Thromboembolic events and anti-tumor necrosis factor therapies
(2012) International Immunopharmacology — Vol. 14, n° 4, p. 444-445 (2012)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 197.4 KB
Details
- Authors
- Abstract
- Thromboembolic (TE) events have been observed in about 4.5% of patients treated with TNF antagonists. It has been suggested that anti-drug antibodies could be involved. However, another mechanism fits more with the available immunochemical data and could lead to practical measures to prevent TE events during anti-TNF therapies. Adverse effects are not related to the type of antagonist, but well to the combination of the inhibition of TNF and the predisposition of some patients to lupus-like reactions, including antiphospholipid syndrome. The overproduction of interferon-α, caused by the inhibition of TNF in these individuals would foster the development of lupus-like syndrome. Therefore, seeking conventional markers of systemic lupus erythematosus (e.g. anti-dsDNA, anti-phospholipid, anti-β<inf>2</inf>- glycoprotein antibodies) before the administration of an anti-TNF could be a prudent measure. © 2012 Elsevier B.V. All rights reserved.
- Affiliations
Citations
Masson, P. (2012). Thromboembolic events and anti-tumor necrosis factor therapies. International Immunopharmacology, 14(4), 444-445. https://doi.org/10.1016/j.intimp.2012.08.018 (Original work published 2012)